专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08603478B2 Anti-RON antibodies 失效
标题翻译：抗RON抗体
公开(公告)号：US08603478B2
公开(公告)日：2013-12-10
申请号：US13177071
申请日：2011-07-06
申请人： Kerry Whalen , Steve Bottega , Andrea Boudrow , Lyne Breault , Ting Chen , James Gifford , May Han , Jinwei Jiang , Lorena Lerner , Qing Liu , Kristan Meetze , Sylvie Vincent , Solly Weiler , William M. Winston, Jr. , Jeno Gyuris
发明人： Kerry Whalen , Steve Bottega , Andrea Boudrow , Lyne Breault , Ting Chen , James Gifford , May Han , Jinwei Jiang , Lorena Lerner , Qing Liu , Kristan Meetze , Sylvie Vincent , Solly Weiler , William M. Winston, Jr. , Jeno Gyuris
IPC分类号： A61K39/395
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.
摘要翻译：公开了结合并抑制人RON（Recepteur d'Origine Nantais）活化的单克隆抗体。抗体可用于治疗与RON活化相关的特定形式的癌症。

2. 发明授权

US08481688B2 Anti-FGFR2 antibodies 失效
标题翻译：抗FGFR2抗体
公开(公告)号：US08481688B2
公开(公告)日：2013-07-09
申请号：US13105521
申请日：2011-05-11
申请人： Zhigang Weng , William M. Winston, Jr. , Ailin Bai , Kristan Meetze , Solly Weiler , Ting Chen , Jeno Gyuris
发明人： Zhigang Weng , William M. Winston, Jr. , Ailin Bai , Kristan Meetze , Solly Weiler , Ting Chen , Jeno Gyuris
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.
摘要翻译：公开了结合和抑制人FGFR2的生物学活性的单克隆抗体。抗体可用于治疗与FGFR2的活化或过表达相关的细胞增殖性疾病和病症，包括某些形式的癌症。

3. 发明申请

US20130165343A1 IDENTIFICATION OF MULTIGENE BIOMARKERS 审中-公开
公开(公告)号：US20130165343A1
公开(公告)日：2013-06-27
申请号：US13775928
申请日：2013-02-25
申请人： AVEO Pharmaceuticals, Inc.
发明人： Murray Robinson , Bin Feng , Richard Nicoletti , Joshua P. Frederick , Lejla Pilipovic
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
摘要： Methods for identifying multigene biomarkers for predicting sensitivity or resistance to an anti-cancer drug of interest, or multigene cancer prognostic biomarkers are disclosed. The disclosed methods are based on the classification of the mammalian genome into 51 transcription clusters, i.e., non-overlapping, functionally relevant groups of genes whose intra-group transcript levels are highly correlated. Also disclosed are specific multigene biomarkers for predicting sensitivity or resistance to tivozanib, or rapamycin, and a specific multigene biomarker for determining breast cancer prognosis, all of which were identified using the methods disclosed herein.

4. 发明授权

US07556796B2 Directed complementation 失效
标题翻译：导向互补
公开(公告)号：US07556796B2
公开(公告)日：2009-07-07
申请号：US11398171
申请日：2006-04-05
申请人： Murray Robinson , Ronan O'Hagan , Karuppiah Kannan , Ti Cai , Maria Isabel Chiu , Lorena Lerner , Jie Lin , Yinghui Zhou
发明人： Murray Robinson , Ronan O'Hagan , Karuppiah Kannan , Ti Cai , Maria Isabel Chiu , Lorena Lerner , Jie Lin , Yinghui Zhou
IPC分类号： A61K49/00 , A61K35/12
CPC分类号： A01K67/0271 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/0331 , C07K14/82 , C12N15/8509 , C12N2830/002
摘要： A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary and sufficient for the tumorigenicity of the tumorigenic mouse cell, and (ii) the inducible promoter is in the uninduced state; and (b) introducing into the cell a recombinant gene of interest that functionally complements the oncogene, thereby restoring tumorigenicity without expression of the inducible recombinant oncogene. Also disclosed is a method of testing a compound for anti-tumor effects. The method includes producing tumorigenic mouse cells the tumorigenicity depends on expression of a recombinant gene of interest, implanting the cells in mice and obtaining tumors from the implanted cells, administering test compounds to the mice, and determining anti-tumor effects, if any, of the compounds.
摘要翻译：公开了一种致瘤性小鼠细胞的产生方法取决于感兴趣的重组基因的方法。该方法包括：（a）提供含有可操作地连接到诱导型启动子的重组癌基因的条件致瘤小鼠细胞，其中（i）重组癌基因的表达对于致瘤性小鼠细胞的致瘤性是必要和足够的，以及（ii）诱导型启动子处于未诱导状态; 和（b）在细胞中引入功能上补充致癌基因的重组基因，从而恢复致瘤性而不表达可诱导的重组癌基因。还公开了测试化合物抗肿瘤作用的方法。该方法包括产生致瘤性小鼠细胞，其致瘤性取决于感兴趣的重组基因的表达，将细胞植入小鼠中并从植入的细胞中获得肿瘤，向小鼠施用测试化合物，并测定抗肿瘤作用（如果有的话）化合物。

5. 发明授权

US10597444B2 Anti-GDF15 antibodies 有权
公开(公告)号：US10597444B2
公开(公告)日：2020-03-24
申请号：US15655263
申请日：2017-07-20
申请人： AVEO Pharmaceuticals, Inc.
发明人： Lorena Lerner , Sandra Abbott , Ailin Bai , Ting Chen , Maria I. Chiu , Qing Liu , Laura Poling , Nianjun Tao , Solly Weiler , Zhigang Weng , William M. Winston, Jr. , Jeno Gyuris
IPC分类号： C07K16/00 , C07K16/22 , C12N15/13 , C12N15/63 , A61P3/02 , A61K39/395 , A61K45/06 , A61K39/00
摘要： Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.

6. 发明申请

US20170137506A1 TREATMENT OF CHRONIC KIDNEY DISEASE AND OTHER RENAL DYSFUNCTION USING A GDF15 MODULATOR 审中-公开
公开(公告)号：US20170137506A1
公开(公告)日：2017-05-18
申请号：US15320101
申请日：2015-06-19
申请人： AVEO Pharmaceuticals, Inc.
发明人： Jeno Gyuris , Lorena Lerner
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , A61K2039/505 , C07K14/475 , C07K2317/76 , C07K2319/30
摘要： The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.

7. 发明授权

US09228021B2 Anti-ErbB3 antibodies 有权
公开(公告)号：US09228021B2
公开(公告)日：2016-01-05
申请号：US13919582
申请日：2013-06-17
申请人： AVEO Pharmaceuticals, Inc.
发明人： Sylvie Vincent , William M. Winston, Jr. , Fang Wang , Solly Weiler , Kristan Meetze , Lyne Breault , Steve Bottega , Ting Chen , Michael DePrima , Christina Fleet , Steven Tyler , Jin-Kyeung Woo , Jeno Gyuris
IPC分类号： C12P21/08 , C07K16/30 , C07K16/32 , A61K39/00
CPC分类号： C07K16/32 , A61K39/39558 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.

8. 发明申请

US20140066603A1 ANTI-RON ANTIBODIES 有权
标题翻译：抗体抗体
公开(公告)号：US20140066603A1
公开(公告)日：2014-03-06
申请号：US14070070
申请日：2013-11-01
申请人： AVEO Pharmaceuticals, Inc.
发明人： Kerry Whalen , Steve Bottega , Andrea Boudrow , Lyne Breault , Ting Chen , James Gifford , May Han , Jinwei Jiang , Lorena Lerner , Qing Liu , Kristan Meetze , Sylvie Vincent , Solly Weiler , William M. Winston, Jr. , Jeno Gyuris
IPC分类号： C07K16/30
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.
摘要翻译：公开了结合并抑制人RON（Recepteur d'Origine Nantais）活化的单克隆抗体。抗体可用于治疗与RON活化相关的特定形式的癌症。

9. 发明授权

US08481687B2 Anti-ErbB3 antibodies 有权
标题翻译：抗ErbB3抗体
公开(公告)号：US08481687B2
公开(公告)日：2013-07-09
申请号：US13082852
申请日：2011-04-08
申请人： Sylvie Vincent , William M. Winston, Jr. , Fang Wang , Solly Weiler , Kristan Meetze , Lyne Breault , Steve Bottega , Ting Chen , Michael DePrima , Christina Fleet , Steven Tyler , Jin-Kyeung Woo , Jeno Gyuris
发明人： Sylvie Vincent , William M. Winston, Jr. , Fang Wang , Solly Weiler , Kristan Meetze , Lyne Breault , Steve Bottega , Ting Chen , Michael DePrima , Christina Fleet , Steven Tyler , Jin-Kyeung Woo , Jeno Gyuris
IPC分类号： C07K16/28
CPC分类号： C07K16/32 , A61K39/39558 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
摘要翻译：公开了结合并抑制表皮生长因子受体相关成分ErbB3 / HER3活化的单克隆抗体。抗体可用于治疗与ErbB3 / HER3的激活相关的细胞增殖性疾病和病症，包括某些形式的癌症。

10. 发明授权

US08273355B2 Hepatocyte growth factor (HGF) binding proteins 有权
公开(公告)号：US08273355B2
公开(公告)日：2012-09-25
申请号：US13051481
申请日：2011-03-18
申请人： William M. Winston, Jr. , S. Kirk Wright , May Han , Lyne Breault , Jie Lin , Bijan Etemad-Gilbertson , Christine Knuehl , Jeno Gyuris , Arnold Horwitz
发明人： William M. Winston, Jr. , S. Kirk Wright , May Han , Lyne Breault , Jie Lin , Bijan Etemad-Gilbertson , Christine Knuehl , Jeno Gyuris , Arnold Horwitz
IPC分类号： A61K39/395
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式